Expert review of pharmacoeconomics & outcomes research
-
Expert Rev Pharmacoecon Outcomes Res · Feb 2010
ReviewModeling healthcare expenditures: overview of the literature and evidence from a panel time-series model.
The rapid growth of healthcare expenditures in the past 40 years in many industrial countries has contributed to an improvement in life expectancy and the quality of life, but has also jeopardized the sustainability of public budgets. For the future, it is important to get more insight into the determinants of this growth. ⋯ Owing to the Baumol effect, healthcare tends to become more expensive over time. How does the demand for healthcare react to this price increase?
-
Expert Rev Pharmacoecon Outcomes Res · Feb 2010
Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
To assess the impact of a range of national and regional initiatives introduced in the North Lancashire Teaching Primary Care Trust (NLTPCT) since 2004 to enhance the quality and efficiency of prescribing proton pump inhibitors (PPIs), statins and ezetimibe. In addition, to suggest additional measures that could be introduced in NLTPCT to further enhance the quality and efficiency of prescribing based on initiatives in other European countries. ⋯ The findings are in line with expectations and do provide examples to other European countries. This includes a high rate of INN prescribing, low reimbursed prices for generic simvastatin and omeprazole and growing utilization of higher strength statins. The high rate of INN prescribing reduces the need for additional measures that have been instigated in other European countries to further enhance the prescribing and dispensing of generics to fully realize the resource benefits. Additional demand side measures are feasible and have already been instigated to conserve resources.